传统与基于人工智能的计算机断层扫描和磁共振成像定量技术用于无创肝纤维化分期
本综述探讨传统与基于人工智能(AI)的CT和MRI定量技术在无创肝纤维化分期中的价值,总结其诊断性能、优势与局限性。文章指出肝活检存在并发症风险和技术限制,CT与MRI已被用于评估肝硬化相关并发症,多种基于CT、MRI的无创方法及AI技术已被应用于肝纤维化分期。
要点
- CT和MRI不仅用于评估肝硬化相关并发症,多种基于CT、MRI的无创方法已被提出用于肝纤维化分期。
- AI技术已被应用于肝纤维化分期,本综述总结其诊断性能、优势与局限性。
- 肝活检存在并发症风险和技术限制,限制了其在筛查和序贯监测中的应用。
核心结论
- 传统与基于AI的CT和MRI定量技术可用于无创肝纤维化分期,本综述总结了其诊断性能、优势与局限性。
研究设计与样本
- 综述,探讨传统与基于AI的CT和MRI定量技术在无创肝纤维化分期中的价值,并总结其诊断性能、优势与局限性;原文未报告检索范围、纳入文献数量与中心数。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Chronic liver disease (CLD) ultimately develops into liver fibrosis and cirrhosis and is a major public health problem globally. The assessment of liver fibrosis is important for patients with CLD for prognostication, treatment decisions, and surveillance. Liver biopsies are traditionally performed to determine the stage of liver fibrosis. However, the risks of complications and technical limitations restrict their application to screening and sequential monitoring in clinical practice. CT and MRI are essential for evaluating cirrhosis-associated complications in patients with CLD, and several non-invasive methods based on them have been proposed. Artificial intelligence (AI) techniques have also been applied to stage liver fibrosis. This review aimed to explore the values of conventional and AI-based CT and MRI quantitative techniques for non-invasive liver fibrosis staging and summarized their diagnostic performance, advantages, and limitations.
引用
- Zheng, He, Zhang, et al. Conventional and artificial intelligence-based computed tomography and magnetic resonance imaging quantitative techniques for non-invasive liver fibrosis staging. Eur J Radiol. 2023. PMID: 37290363. doi:10.1016/j.ejrad.2023.110912
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。